Eric Feldman
Plus aucun poste en cours
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Peter van Vlasselaer | M | 64 |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | 5 ans |
| peter vlasselaer | M | - |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | 6 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Franklin Berger | M | 74 | 10 ans | |
| John McLaughlin | M | 72 | 9 ans | |
| John Orwin | M | 59 | 9 ans | |
| Kirk D. Schumacher | M | - | 11 ans | |
| Jean Liu | F | 55 | 9 ans | |
| Christopher Boerner | M | 53 | 5 ans | |
| Dennis Benjamin | M | - | 3 ans | |
| Naomi Hunder | M | 54 | 7 ans | |
| Leslie Aberman | F | - | 8 ans | |
| Stanford Peng | M | 53 | 1 ans | |
| Brandi Robinson | F | - | 2 ans | |
| David Fontana | M | - | - | |
| Robert Lechleider | M | - | 4 ans | |
| Elizabeth Bekiroglu | F | 54 | 5 ans | |
| Eric Sievers | M | 60 | 9 ans | |
| Florian Fischer | M | 56 |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | - |
| Tina Albertson | M | 51 | 5 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 19 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Eric Feldman
- Réseau Personnel
